Unlocking the Potential of APPL1: A drug Target and Biomarker

Target Name: APPL1

NCBI ID: G26060

APPL1

Other Name(s): Adapter protein containing PH domain, PTB domain and leucine zipper motif 1 | adaptor protein containing pH domain, PTB domain and leucine zipper motif 1 | adaptor protein, phosphotyrosine interaction, PH domain and leucine zipper containing 1 | APPL | Adaptor protein containing pH domain, PTB domain and leucine zipper motif | adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 1 | DP13A_HUMAN | dip13-alpha | Signaling adaptor protein DIP13alpha | adapter protein containing PH domain, PTB domain and leucine zipper motif 1 | DCC-interacting protein 13-alpha | MODY14 | signaling adaptor protein DIP13alpha | Dip13-alpha | AKT2 interactor | DIP13alpha | Adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 1

Unlocking the Potential of APPL1: A drug Target and Biomarker

Apoptosis, the process of programmed cell death, is a natural response to various stimuli, including stress, DNA damage, and infections. When cells reach a certain level of stress and cannot recover, they undergo apoptosis, leading to the death of cells and the formation of apoptotic bodies. In the context of cancer, uncontrolled apoptosis can contribute to the development and progression of cancer. Therefore, understanding the regulation of apoptosis is critical for the development of effective cancer treatments.

One of the key proteins involved in regulating apoptosis is APPL1, a transmembrane protein that contains a PH domain, a PTB domain, and a leucine zipper motif 1 (LZM1). The PH domain is a conserved structural domain that is involved in various cellular processes, including cell signaling and cytoskeletal organization. The PTB domain is a unique structural domain that is found in a variety of proteins, including APPL1, and is involved in protein-protein interactions and Client-protein interactions. The LZM1 domain is a short sequence of 11 amino acids that is located at the C-terminus of APPL1 and is known for its role in regulating apoptosis.

APPL1 functions as an adaptor protein that can interact with various protein clients and regulators. One of its most significant functions is its role in regulating apoptosis. APPL1 has been shown to play a critical role in the regulation of apoptosis by affecting the expression of genes involved in cell death processes. For example, studies have shown that APPL1 can interact with and regulate the activity of the protein BCL-2, which is a well-known regulator of apoptosis.

In addition to its role in regulating apoptosis, APPL1 has also been shown to be a potential drug target and biomarker. The PH domain of APPL1 has been shown to be involved in various cellular processes, including the regulation of ion channels and the modulation of gene expression. Therefore, compounds that can modulate the activity of APPL1 by interacting with its PH domain may be useful for targeting cancer cells that are dependent on APPL1 for their survival.

The PTB domain of APPL1 is also an attractive target for drug development due to its unique structural features. The PTB domain is a hydrophobic domain that can interact with various proteins and small molecules, including drugs that are designed to modulate protein-protein interactions. Therefore, compounds that can interact with the PTB domain of APPL1 may be useful for targeting proteins that are dependent on this domain for their activity.

The LZM1 domain of APPL1 is also a potential drug target and biomarker. The LZM1 domain is a short sequence of 11 amino acids that is located at the C-terminus of APPL1 and can interact with various proteins and small molecules. Therefore, compounds that can interact with the LZM1 domain of APPL1 may be useful for targeting proteins that are dependent on this domain for their activity.

Conclusion

In conclusion, APPL1 is a protein that plays a critical role in regulating apoptosis and has the potential to be a drug target and biomarker. The PH domain, PTB domain, and LZM1 domain of APPL1 have unique structural features that make them attractive targets for drug development. Further research is needed to fully understand the functions of APPL1 and its potential as a drug target and biomarker.

Protein Name: Adaptor Protein, Phosphotyrosine Interacting With PH Domain And Leucine Zipper 1

Functions: Multifunctional adapter protein that binds to various membrane receptors, nuclear factors and signaling proteins to regulate many processes, such as cell proliferation, immune response, endosomal trafficking and cell metabolism (PubMed:26583432, PubMed:15016378, PubMed:26073777, PubMed:19661063, PubMed:10490823). Regulates signaling pathway leading to cell proliferation through interaction with RAB5A and subunits of the NuRD/MeCP1 complex (PubMed:15016378). Functions as a positive regulator of innate immune response via activation of AKT1 signaling pathway by forming a complex with APPL1 and PIK3R1 (By similarity). Inhibits Fc-gamma receptor-mediated phagocytosis through PI3K/Akt signaling in macrophages (By similarity). Regulates TLR4 signaling in activated macrophages (By similarity). Involved in trafficking of the TGFBR1 from the endosomes to the nucleus via microtubules in a TRAF6-dependent manner (PubMed:26583432). Plays a role in cell metabolism by regulating adiponecting and insulin signaling pathways (PubMed:26073777, PubMed:19661063, PubMed:24879834). Required for fibroblast migration through HGF cell signaling (By similarity). Positive regulator of beta-catenin/TCF-dependent transcription through direct interaction with RUVBL2/reptin resulting in the relief of RUVBL2-mediated repression of beta-catenin/TCF target genes by modulating the interactions within the beta-catenin-reptin-HDAC complex (PubMed:19433865)

The "APPL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about APPL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets